Peregrine Capital Management LLC Has $4.05 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Peregrine Capital Management LLC lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 47.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 49,439 shares of the medical equipment provider’s stock after selling 44,759 shares during the quarter. Peregrine Capital Management LLC owned 0.07% of Lantheus worth $4,047,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC increased its stake in Lantheus by 29.3% in the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock valued at $128,000 after buying an additional 298 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in Lantheus by 43.1% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,196 shares of the medical equipment provider’s stock valued at $507,000 after buying an additional 1,564 shares during the period. Oppenheimer & Co. Inc. acquired a new position in Lantheus in the 1st quarter valued at approximately $226,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Lantheus by 3.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider’s stock valued at $1,162,000 after buying an additional 400 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in Lantheus by 11.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 192,686 shares of the medical equipment provider’s stock valued at $18,870,000 after buying an additional 20,104 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insiders Place Their Bets

In related news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Lantheus Stock Performance

Shares of LNTH opened at $57.33 on Wednesday. The company’s fifty day moving average is $54.23 and its 200-day moving average is $71.05. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 15.25 and a beta of 0.09. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The company had revenue of $92.51 million for the quarter. Equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Mizuho dropped their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, August 7th. B. Riley dropped their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday. Finally, The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Hold” and an average price target of $74.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.